Pharmacokinetics and Pharmacodynamics of Fluoroquinolones

Overview

Journal Drugs

Specialty Pharmacology

Date 1999 Dec 20

PMID 10553702

Citations 63

Authors

J Turnidge

Affiliations

Soon will be listed here.

Abstract

The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-lives (50 to 98%) and volumes of distribution >1.5 L/kg. There is considerable variation in elimination pattern between fluoroquinolone agents, ranging from predominant renal excretion to extensive hepatic metabolism. Protein binding also varies between agents. Tissue concentrations often exceed plasma concentrations, while concentrations in CSF are modest in the presence of inflammation. Fluoroquinolones show concentration-dependent killing in vitro, and animal models have demonstrated the 24-hour AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio to be the best predictor of bacterial killing in vivo, with the peak plasma concentration (Cmax)/MIC ratio being important for some bacteria, to prevent the emergence of resistance during treatment. Animal models and human studies with ciprofloxacin, grepafloxacin and levofloxacin show that a 24-hour AUC/MIC ratio of about 100, or a Cmax/MIC ratio of about 10 gives maximum clinical and bacteriological efficacy. These values can be used to predict the efficacy of different agents against different pathogens, and to define pharmacodynamic 'breakpoints'.

Citing Articles

Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture.

Duman E, Muller-Deubert S, Pattappa G, Stratos I, Sieber S, Clausen-Schaumann H Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005998 PMC: 11858458. DOI: 10.3390/ph18020184.

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.

Zhou Q, Pu N, Xu G, Liu H, Jia X, Wang X PLoS One. 2025; 20(1):e0315512.

PMID: 39746086 PMC: 11694965. DOI: 10.1371/journal.pone.0315512.

Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs.

Buddington K, Pierzynowski S, Holmes W, Buddington R Antibiotics (Basel). 2024; 13(1).

PMID: 38275322 PMC: 10812520. DOI: 10.3390/antibiotics13010012.

A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study.

So-Ngern A, Jirajariyavej S, Thuncharoon H, Khunthupat N, Chantarojanasiri T, Montakantikul P Clin Transl Sci. 2023; 16(12):2709-2718.

PMID: 37853952 PMC: 10719478. DOI: 10.1111/cts.13665.

Pharmacokinetics in Critically Ill Children with Acute Kidney Injury.

Raina M, Ashraf A, Soundararajan A, Mandal A, Sethi S Paediatr Drugs. 2023; 25(4):425-442.

PMID: 37266815 DOI: 10.1007/s40272-023-00572-z.

References

Kozawa O, Uematsu T, Matsuno H, Niwa M, Nagashima S, Kanamaru M . Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrob Agents Chemother. 1996; 40(12):2824-8. PMC: 163630. DOI: 10.1128/AAC.40.12.2824. View

Jaehde U, Sorgel F, Stephan U, Schunack W . Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother. 1994; 38(5):1129-33. PMC: 188162. DOI: 10.1128/AAC.38.5.1129. View

Forrest A, CHODOSH S, Amantea M, Collins D, Schentag J . Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1998; 40 Suppl A:45-57. DOI: 10.1093/jac/40.suppl_1.45. View

Ritz M, Lode H, Fassbender M, Borner K, Koeppe P, Nord C . Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother. 1994; 38(3):455-9. PMC: 284479. DOI: 10.1128/AAC.38.3.455. View

Blaser J, Stone B, Groner M, Zinner S . Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987; 31(7):1054-60. PMC: 174871. DOI: 10.1128/AAC.31.7.1054. View

Stuht H, Lode H, Koeppe P, Rost K, Schaberg T . Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother. 1995; 39(5):1045-9. PMC: 162680. DOI: 10.1128/AAC.39.5.1045. View

Johnson D, Jones R, Erwin M . In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones. Diagn Microbiol Infect Dis. 1993; 17(1):79-83. DOI: 10.1016/0732-8893(93)90076-j. View

Kivisto K, Neuvonen P . Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother. 1992; 36(2):489-91. PMC: 188466. DOI: 10.1128/AAC.36.2.489. View

Israel D, Gillum J, Turik M, Harvey K, Ford J, Dalton H . Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1993; 37(10):2193-9. PMC: 192249. DOI: 10.1128/AAC.37.10.2193. View

10.

Jones R, Aldridge K, Barry A, Fuchs P, Gerlach E, Pfaller M . Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagn Microbiol Infect Dis. 1988; 10(4):221-40. DOI: 10.1016/0732-8893(88)90094-6. View

11.

Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View

12.

Prosser B, Beskid G . Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates. Diagn Microbiol Infect Dis. 1995; 21(1):33-45. DOI: 10.1016/0732-8893(94)00087-d. View

13.

Forrest A, Nix D, Ballow C, Goss T, Birmingham M, Schentag J . Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37(5):1073-81. PMC: 187901. DOI: 10.1128/AAC.37.5.1073. View

14.

Teng R, Dogolo L, Willavize S, Friedman H, Vincent J . Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997; 39 Suppl B:87-92. DOI: 10.1093/jac/39.suppl_2.87. View

15.

Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y . Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother. 1995; 39(12):2635-40. PMC: 163003. DOI: 10.1128/AAC.39.12.2635. View

16.

Chien S, Chow A, Natarajan J, Williams R, Wong F, Rogge M . Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother. 1997; 41(7):1562-5. PMC: 163959. DOI: 10.1128/AAC.41.7.1562. View

17.

Felmingham D, Robbins M, Ingley K, MATHIAS I, Bhogal H, Leakey A . In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997; 39 Suppl B:43-9. DOI: 10.1093/jac/39.suppl_2.43. View

18.

Craig W, Ebert S . Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990; 74:63-70. View

19.

Preston S, Drusano G, BERMAN A, Fowler C, Chow A, Dornseif B . Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998; 42(5):1098-104. PMC: 105752. DOI: 10.1128/AAC.42.5.1098. View

20.

Nakane T, Iyobe S, Sato K, Mitsuhashi S . In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother. 1995; 39(12):2822-6. PMC: 163041. DOI: 10.1128/AAC.39.12.2822. View